Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.59 |
| ▸ | APP | P05067 | 2/20 | 0.59 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.57 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.57 |
| ▸ | ESRRG | P62508 | 9/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7496431 | 0.98 | ESR1 (0.57) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL9910293 | 0.85 | HSD17B1 (0.61) | ESR1ESR2HSD17B1HSD17B2ESRRG | |
| SCHEMBL15177332 | 0.83 | RAB9A (0.73) | ESRRGCYP3A4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL220043 | 0.83 | CYP3A4 (0.54) | HSD17B1HSD17B2CYP3A4CYP2A6CYP2C9 | |
| SCHEMBL2083801 | 0.82 | MEN1 (0.72) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL3097763 | 0.82 | RAB9A (0.67) | CYP3A4CYP2A6CYP2C9CYP2C19HDAC6 | |
| SCHEMBL2254356 | 0.81 | HDAC6 (0.64) | CYP3A4CYP2A6CYP2C9CYP2C19HDAC6 | |
| SCHEMBL1356959 | 0.81 | LMNA (0.70) | CYP3A4CYP2A6CYP2C9CYP2C19HDAC6 | |
| SCHEMBL497984 | 0.80 | ESRRG (0.56) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL10269888 | 0.80 | TP53 (0.57) | HSD17B1HSD17B2CYP3A4CYP2A6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171444-A1 | Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2014-06-19 | — | — | US | disclosed |
| US-8664255-B2 | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2014-03-04 | — | — | US | disclosed |
| US-20100113477-A1 | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof | TEXAS A&M UNIVERSITY SYSTEM, THE | 2010-05-06 | — | — | US | disclosed |
| WO-2010047774-A2 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS MALATE SYNTHASE, METHODS OF MARKING AND USES THEREOF | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20060287356-A1 | dietetics or antidiabetic agents such as 4-hydroxy-3-(4'-hydroxy-1,1'-biphenyl-4-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-5-carbonitrile, used for prophylaxis of metabolic disorders | IYENGAR RAJESH R | 2006-12-21 | — | — | US | disclosed |
| US-7119205-B2 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | ABBOTT LABORATORIES (US) | 2006-10-10 | — | — | US | disclosed |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | ABBVIE INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113477-A1 | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof | ME3, ME1, MDH1 | ESR1 4285/4885ESR2 4437/4885APP 4198/4885 |
| US-20060287356-A1 | dietetics or antidiabetic agents such as 4-hydroxy-3-(4'-hydroxy-1,1'-biphenyl-4-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-5-carbonitrile, used for prophylaxis of metabolic disorders | GPR119, FABP4, ADIPOR1 | ESR1 2031/4885ESR2 1703/4885APP 3437/4885 |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | PRKAG1, PRKAG3, PRKAG2 | ESR1 2361/4885ESR2 2486/4885APP 2585/4885 |
| US-20140171444-A1 | Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof | ME3, ME1, MDH1 | ESR1 4285/4885ESR2 4437/4885APP 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.